Short-course chemoprophylaxis for tuberculosis

Clinics in Chest Medicine

Volumn 18, Issue 1, 1997, Pages 115-122

  Bishai, W R ^a   Chaisson, R E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE;

CHEMOPROPHYLAXIS; DISEASE ACTIVITY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT PLANNING; TUBERCULOSIS;

EID: 0030984274     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(05)70360-9     Document Type: Article

References (56)

1. Alland D. Kalkut G.E. A.R. Moss Transmission of tuberculosis in New York City: An analysis by DNA fingerprinting and conventional epidemiologic methods N Engl J Med 330 1994 1710 1716
2. Anonymous Chemoprophylaxis for tuberculosis Tubercle 61 1981 69 72
3. P.F. Barnes H. El-Hajj S. Preston-Martin Transmission of tuberculosis among the urban homeless JAMA 275 1996 305 307
4. Bates JH: The tuberculin skin test and preventive treatment for tuberculosis. In Rom WN, Garay SM (eds): Tuberculosis. Boston, Little, Brown and Co, pp 865–871
5. J.B. Bass L.S. Farer P.C. Hopewell Treatment of tuberculosis and tuberculosis infection in adults and children Am J Respir Crit Care Med 149 1994 1359 1374
6. W.R. Bishai N.M.H. Graham S. Harrington Rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis N Engl J Med 334 1996 1573 1576
7. T.F. Blaschke M.H. Skinner The clinical pharmacokinetics of rifabutin Clin Infect Dis 22 suppl 1 1996 S15 S22
8. A.B. Bloch G.M. Cauthen I.M. Onorato Nationwide survey of drug-resistant tuberculosis in the United States JAMA 271 1994 665 671
9. J. Bradbury M. tuberculosis genome to be sequenced Lancet 347 1996 890
10. C. Braden Molecular epidemiology of tuberculosis in a rural population Symposium C57 1996 American Thoracic Society Meeting New Orleans
11. L. Chapuis B. Ji C. Truffot-Pernot Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice Am J Respir Crit Care Med 150 1994 1355 1362
12. B.R. Chatterjee A non-acid fast coccoid precursor— possible cultivable phase of Mycobacterium leprae. Leprosy in India 48 1976 398
13. G.W. Comstock S.F. Woolpert C. Baum Isoniazid prophylaxis among Alaskan Eskimos: A progress report Am Rev Respir Dis 110 1974 195 197
14. G.W. Comstock C. Baum D.E. Snider Jr Isoniazid prophylaxis among Alaskan Eskimos: A final report of the Bethel isoniazid studies Am Rev Respir Dis 119 1979 827 830
15. G.W. Comstock S.F. Woolpert Preventive therapy G.P. Kubica L.G. Wayne The Mycobacteria: A Sourcebook 1984 Marcel Dekker New York 1071 1082
16. H.J. Corper M.L. Cohn The viability and virulence of old cultures of tubercle bacilli: Studies on 12-year broth cultures maintained at incubator temperature American Reviews of Tuberculosis 28 1933 856 874
17. J. DeMaio Y. Zhang C. Ko A stationary phase, stress response sigma factor from Mycobacterium tuberculosis. Proc Natl Acad Sci USA 93 1996 2790 2794
18. D. deWit M. Wooton J. Dhillon The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis Tuber Lung Dis 76 1995 555 562
19. J. Dhillon J.M. Dickinson J.A. Guy Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis Tuber Lung Dis 73 1992 116 123
20. J. Dhillon J.M. Dickinson K. Sole Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide Antimicrob Agents Chemother 40 1996 552 555
21. J.M. Dickinson D.A. Mitchison In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis Tubercle 68 1987 113 118
22. S.H. Ferebee Controlled chemoprophylaxis trial in tuberculosis: A general review Advances in Tuberculosis Research 17 1970 28 106
23. S.H. Ferebee F.W. Mount Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts Am Rev Respir Dis 85 1962 490 521
24. S.H. Ferebee F.W. Mount F.J. Murray A controlled trial of isoniazid prophylaxis in mental institutions Am Rev Respir Dis 88 1963 161 175
25. Gomez J, DeMaio J, Ko C, et al: Sporulation regulatory gene homologues in M. tuberculosis and M. leprae. Program of the Thirty-first U.S.-Japan Tuberculosis Research Conference, Nagasaki, Japan, 1996
26. L.J. Gonzales-Montaner S. Natal P. Yongchalyud Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: A multinational, randomized, comparative study versus rifampicin Tuber Lung Dis 75 1994 341 347
27. N.M.H. Graham N. Galai K.E. Nelson Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease Arch Intern Med 156 1996 889 894
28. Graham NMH, Harrington S, Bishai W, et al: Tuberculosis transmission clusters and pseudoclusters in Baltimore. Presented at 1996 American Thoracic Society Meeting, New Orleans, LA, 1996
29. J. Grosset The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy Tubercle 59 1978 287 297
30. J. Grosset C. Truffot-Pernot C. Lacroix Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice Antimicrob Agents Chemother 36 1992 548 551
31. N. Halsey J. Coberly J. Atkinson Twice-weekly isoniazid for TB prophylaxis [abstract PB 0681] Int Conf AIDS 10 1994 167
32. L.B. Heifets P.J. Lindholm-Levy M.D. Iseman Rifabutin: Minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis 137 1988 719 721
33. Hong Kong Chest Service and British Medical Research Council A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong Am Rev Respir Dis 145 1992 36 41
34. International Union Against Tuberculosis Committee on Prophylaxis Efficacy of various durations of isoniazid preventive therapy for tuberculosis: 5 years of follow-up in the IUAT trial Bull WHO 60 1982 555 564
35. M.D. Iseman Less is more: Short-course preventive therapy for tuberculosis Am Rev Respir Dis 140 1989 1197
36. Jabe`s D. C. Della Bruna R. Rossi Effectiveness of rifabutin alone or in combination with isoniazid in the preventive therapy of mouse tuberculosis Antimicrob Agents Chemother 38 1994 2346 2350
37. B. Ji C. Truffot-Pernot C. Lacroix Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice Am Rev Respir Dis 148 1993 1541 1546
38. Lambombardi VL, Cataldo-Caputzal L, Cohen R, et al: Induction of resistance to rifampin by rifabutin in isolates of Mycobacterium tuberculosis. Abstract of the 96th ASM General Meeting, New Orleans, 1996 [Abstract U-73], p 113, 1996
39. H.F. LeCoeur C. Truffot-Pernot J.H. Grosset Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide Am Rev Respir Dis 140 1989 1189 1193
40. M.P. Lutfey V. Della-Latta L.A. Kapur Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS Am J Respir Crit Care Med 153 1996 837 840
41. R.M. McCune F.M. Feldmann H.P. Lambert Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues J Exp Med 123 1966 445 468
42. N. Mor B. Simon N. Mezo L. Heifets Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages Antimicrob Agents Chemother 39 1995 2073 2077
43. C.M. Nolan D.L. Williams M.D. Gave Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis Am J Respir Crit Care Med 152 1995 1067 1071
44. A.R. Rich The Pathogenesis of Tuberculosis ed 1 1944 Charles C Thomas Springfield, IL
45. P.M. Small P.C. Hopewell S.P. Singh The epidemiology of tuberculosis in San Francisco: A population-based study using conventional and molecular methods N Engl J Med 330 1994 1703 1709
46. D.E. Snider Jr G.J. Caras J.P. Koplan Preventive therapy with isoniazid: Cost-effectiveness of different durations of therapy JAMA 255 1986 1579 1583
47. D.E. Snider Jr G.J. Caras Isoniazid-associated hepatitis deaths: A review of available information Am Rev Respir Dis 145 1992 494 497
48. J.L. Stanford Much's granules revisited Tubercle 68 1987 241 242
49. G.J.J. Veening Long-term isoniazid prophylaxis. Controlled trial of isoniazid prophylaxis after recent tuberculin conversion in young adults Bulletin of the International Union Against Tuberculosis and Lung Diseases 41 1968 169 171
50. L.G. Wayne Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions Am Rev Respir Dis 114 1976 807 811
51. L.G. Wayne Synchronized replication of Mycobacterium tuberculosis. Infect Immun 17 1977 528 530
52. L.G. Wayne Dormancy of Mycobacterium tuberculosis and latency of disease Eur J Clin Microbiol Infect Dis 13 1977 908 914
53. L.G. Wayne L.G. Hayes An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence Infect Immun 64 1996 2062 2069
54. L.G. Wayne H.A. Sramek Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 38 1994 2054 2058
55. A.C. Weltman S.P. Righi G.T. DiFerdinando Jr Rifampicin-resistant Mycobacterium tuberculosis. Lancet 345 1995 1513
56. Y. Yuan D.D. Crane C.E. Barry III Stationary-phase associated protein expression in Mycobacterium tuberculosis: The function of the mycobacterial α-crystallin homologue J Bacteriol 178 1996 4484 4492